Bristol-Myers Squibb Company (BMY) is Driving Growth Through Strategic Acquisitions
Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other ...
Read This Before Considering Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming US$0.60 Dividend
Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...
Bristol-Myers wins FDA nod for Opdivo lung cancer indication
Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.
stocknews17h
3 Pharmaceutical Stocks That Could Lead the Next Drug Revolution
The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...
The Pharma Letter3h
FDA approves Opdivo for lung cancer before and after surgery
Bristol Myers Squibb has received FDA approval for Opdivo (nivolumab) combined with chemotherapy as a perioperative treatment ...
Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval
Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...
bovnews18h
Why Did Bristol-Myers Squibb Co (BMY) Stock See 34.20% Surge in the Last 90 Days?
On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...
Nasdaq2d
BMY Quantitative Stock Analysis
Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our P/B Growth Investor model based on the published ...
Zacks.com on MSN15h
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
Bristol Myers Squibb (BMY) closed at $54.20 in the latest trading session, marking a +0.82% move from the prior day. This change outpaced the S&P 500's 0.17% loss on the day. Meanwhile, the Dow lost 0 ...
Strategic Focus and BMY Collaboration Bolster Prime Medicine’s Financial Outlook: Hold Rating Affirmed
Morgan Stanley analyst Terence Flynn has maintained their neutral stance on PRME stock, giving a Hold rating today. Terence Flynn’s ...
bovnews3d
BMY’s Latest Twist: What’s Fueling the Unexpected Shifts in Bristol-Myers Squibb Co’s Stock Price?
On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...